Safety and activity of Diakine DK210 (EGFR), a next generation tumor-targeted IL2 x IL10 dual immunocytokine, in patients with advanced cancer: Initial results of the phase 1 first-in-human trial.

Wednesday, June 19, 2024

Dr. Douglas Orr

Click the above link to view the abstract.

ASCO 2024 Poster for Trial 23-08

ASCO 2024 Poster for Trial 23-08